From Financial Modeling Prep: 2025-04-25 14:00:00

X4 Pharmaceuticals, a Nasdaq-listed company under the ticker symbol XFOR, is making strides in the biopharmaceutical industry with its Phase 3 clinical trial for mavorixafor, a treatment for rare immune system diseases like chronic neutropenic disorders.

To attract and retain top talent, X4 Pharmaceuticals recently announced inducement awards for new employees under its 2019 Inducement Equity Incentive Plan. These awards include stock options to purchase 450,471 shares of common stock.

In a strategic move to enhance stock performance and meet exchange listing requirements, X4 Pharmaceuticals is planning a reverse stock split on April 28, 2025. This initiative will involve exchanging 1 share for every 30 shares, potentially increasing the per-share price.

Financially, X4 Pharmaceuticals has a debt-to-equity ratio of approximately 3.53, indicating a higher reliance on debt financing. However, the company boasts a strong current ratio of about 3.41, showcasing its ability to cover short-term liabilities with short-term assets and maintain financial stability.



Read more at Financial Modeling Prep:: X4 Pharmaceuticals’ Strategic Moves and Financial …